tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Rapport Therapeutics assigned Buy rating at Goldman Sachs
PremiumThe FlyRapport Therapeutics assigned Buy rating at Goldman Sachs
2M ago
Premium
Company Announcements
Rapport Therapeutics Announces Public Offering Agreement
2M ago
Rapport Therapeutics 9.62M share Secondary priced at $26.00
Premium
The Fly
Rapport Therapeutics 9.62M share Secondary priced at $26.00
2M ago
EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
PremiumThe FlyEchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
2M ago
Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX
Premium
The Fly
Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX
2M ago
Rapport Therapeutics price target raised to $34 from $31 at H.C. Wainwright
Premium
The Fly
Rapport Therapeutics price target raised to $34 from $31 at H.C. Wainwright
2M ago
PremiumRatingsBuy Rating for Rapport Therapeutics Driven by Upcoming Trial Milestone and Strong Pipeline Potential
3M ago
Premium
Company Announcements
Rapport Therapeutics Reports Q2 2025 Financials and Progress
3M ago
Premium
Company Announcements
Rapport Therapeutics Reports Q2 Results and Updates
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100